- Home
- GNPX vs KAVL Comparison
GNPX vs KAVL Comparison
Compare GNPX & KAVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- KAVL
- Stock Information
- Founded
- GNPX 2009
- KAVL 1998
- Country
- GNPX United States
- KAVL United States
- Employees
- GNPX N/A
- KAVL N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- KAVL Medicinal Chemicals and Botanical Products
- Sector
- GNPX Health Care
- KAVL Health Care
- Exchange
- GNPX Nasdaq
- KAVL Nasdaq
- Market Cap
- GNPX 10.8M
- KAVL 9.6M
- IPO Year
- GNPX 2018
- KAVL N/A
- Fundamental
- Price
- GNPX $5.85
- KAVL $0.53
- Analyst Decision
- GNPX
- KAVL
- Analyst Count
- GNPX 0
- KAVL 0
- Target Price
- GNPX N/A
- KAVL N/A
- AVG Volume (30 Days)
- GNPX 1.8M
- KAVL 163.0K
- Earning Date
- GNPX 11-14-2025
- KAVL 09-16-2025
- Dividend Yield
- GNPX N/A
- KAVL N/A
- EPS Growth
- GNPX N/A
- KAVL N/A
- EPS
- GNPX N/A
- KAVL N/A
- Revenue
- GNPX N/A
- KAVL $1,127,037.00
- Revenue This Year
- GNPX N/A
- KAVL N/A
- Revenue Next Year
- GNPX N/A
- KAVL N/A
- P/E Ratio
- GNPX N/A
- KAVL N/A
- Revenue Growth
- GNPX N/A
- KAVL N/A
- 52 Week Low
- GNPX $4.60
- KAVL $0.40
- 52 Week High
- GNPX $117.50
- KAVL $1.55
- Technical
- Relative Strength Index (RSI)
- GNPX 57.62
- KAVL 41.86
- Support Level
- GNPX $7.71
- KAVL $0.50
- Resistance Level
- GNPX $9.89
- KAVL $0.61
- Average True Range (ATR)
- GNPX 1.35
- KAVL 0.04
- MACD
- GNPX -0.24
- KAVL -0.01
- Stochastic Oscillator
- GNPX 43.95
- KAVL 15.97
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.